一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2026-011 号 一心堂药业集团股份有限公司 关于使用部分暂时闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司")于2025年5月21日召开2024年年度股东会， 审议通过《关于使用部分暂时闲置自有资金进行现金管理的议案》，同意公司及全资子公司使 用额度不超过人民币25亿元的闲置自有资金进行现金管理（包括但不限于购买一年期以内的固 定收益型或保本浮动收益型理财产品、大额存单、定期存款、通知存款、协定存款等），相关 额度在投资期限内任一时点的现金管理金额(含前述投资的收益进行再投资的相关金额)不超过 25亿元人民币。在上述额度内，资金可以滚动使用，在额度范围内授权董事长具体办理实施相 关事项。 一、现金管理到期收回情况 根据 2024 年年度股东会决议，公司与相关银行签署合同，使用部分暂时闲置自有资金进 行现金管理，现部分产品到期收回，基本情况如下： | 签约银行 名称 | 产品名称 | 认购金额 （万元） | ...

Group 1 - The company, Yixin Tang, primarily operates in the pharmaceutical retail chain business [2] - In addition to pharmaceuticals, the company has expanded into non-pharmaceutical categories, including beauty, personal care, maternal and infant products, convenience items, and food [2]

Core Viewpoint - YXTT (One Heart Hall) expects a net profit attributable to shareholders of between 260 million and 330 million yuan for the fiscal year 2025, representing a growth of 127.79% to 189.12% compared to the previous year [1] Group 1 - The total number of direct chain stores is projected to be 11,112 by December 31, 2025, reflecting a net decrease of 386 stores [1] - To enhance operational efficiency and profitability, the company is implementing refined management practices and a series of measures to optimize resource allocation, ensuring that expenditure aligns with business objectives [1]

Policy Developments - The National Health Commission released the "Guidelines for Clinical Application of New Antitumor Drugs (2025 Edition)" to standardize the clinical use of new antitumor drugs, which include small molecule targeted drugs and monoclonal antibodies [2] Drug and Device Approvals - North China Pharmaceutical announced it received a drug registration certificate for Tacrolimus capsules (0.5mg, 1mg), which is an immunosuppressant used to prevent organ transplant rejection [4] - A new lung cancer early diagnosis kit developed by the Hangzhou Institute of Medicine has been approved for market release, potentially improving early diagnosis rates for lung cancer [5] Financial Reports - YaoXingTang projected a net profit of 260 million to 330 million yuan for 2025, representing a year-on-year increase of 127.79% to 189.12%, driven by improved operational efficiency and resource allocation [7] - MaiDe Medical expects a revenue of approximately 447 million yuan for 2025, marking a year-on-year increase of about 62.81%, and anticipates a net profit of around 66.52 million yuan, indicating a turnaround from previous losses [8] Capital Market Activities - Tongrentang Medical submitted an IPO application to the Hong Kong Stock Exchange, with CICC as the sponsor [10] - New Jingzhiyuan Biotech completed over 200 million yuan in Series B financing, led by Xingze Capital and a well-known industry fund [11] Industry Developments - Over 40% of county-level traditional Chinese medicine hospitals have initiated the establishment of county medical communities, with a total of 3,099 such communities formed across 2,199 counties and cities [13] - The National Health Commission reported that all tertiary public traditional Chinese medicine hospitals have achieved full coverage in pediatrics, enhancing health services for children and the elderly [14]

登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码：002727 股票简称：一心堂 公告编号：2026-010号 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为正值且属于同向上升50%以上情形 （1）以区间数进行业绩预告的 四、风险提示 本次业绩预告是公司财务部门初步核算的结果，具体财务数据将在公司2025年年度报告中详细披露。敬 请广大投资者审慎决策，注意投资风险。 特此公告。 一心堂药业集团股份有限公司 单位：万元 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计。公司已就本次业绩预告情况与年报审计会计师事务所进行沟通， 公司与会计师事务所对于本次业绩预告不存在分歧。 三、业绩变动原因说明 公司门店拓展方面，截至2025年12月31日，公司拥有直营连锁门店11,112家，全年净减少386家。2025 年，通过精细化管理和一系列措施，优化资源配置，确保费用支出与业务目标相匹配，从而提高公司运 营效率和盈利能力。 2025年 ...

证券日报网讯 1月26日，一心堂发布2025年度业绩预告称，公司预计2025年归属于上市公司股东的净利 润为26，000万元～33，000万元，比上年同期增长127.79%～189.12%，上年同期为11，413.84万元。 （文章来源：证券日报） ...

Core Viewpoint - YXTT (One Heart Hall) forecasts a net profit of 260 million to 330 million yuan for 2025, representing a year-on-year growth of 127.79% to 189.12% [1] Group 1: Financial Performance - The expected net profit for 2025 is between 260 million and 330 million yuan, indicating significant growth compared to previous years [1] - The company aims to enhance operational efficiency and profitability through refined management and resource optimization [1] Group 2: Store Operations - As of December 31, 2025, YXTT plans to operate 11,112 directly-operated stores, with a net decrease of 386 stores throughout the year [1] - The focus for 2025 will be on improving the operational quality of existing stores, enhancing category management, customer health management, service capabilities, and inter-store collaboration [1]

Core Viewpoint - Several companies are projecting significant increases in net profit for 2025, with some expecting growth rates exceeding 300% compared to the previous year [1] Group 1: Companies with High Profit Growth Projections - Youyou Group anticipates a net profit increase of 357%-420% for 2025 [1] - Sanofi Health expects a net profit growth of 311% for 2025 [1] - Fujilai forecasts a net profit increase of 282.17%-296.8% for 2025 [1] - Zongyi Co. predicts a net profit growth of approximately 264.05% for 2025 [1] - Aiko Optoelectronics expects a net profit increase of 262.52%-345.2% for 2025 [1] Group 2: Companies with Moderate to High Profit Growth Projections - Pulit anticipates a net profit increase of 155.76%-194.73% for 2025 [1] - Zhongxing Junye expects a net profit growth of 134.32%-173.37% for 2025 [1] - Yixin Hall forecasts a net profit increase of 127.79%-189.12% for 2025 [1] - Bangji Technology anticipates a net profit growth of 119.43%-169.3% for 2025 [1] - Hengyu Environmental expects a net profit increase of 104.14% for 2025 [1] Group 3: Companies with Lower Profit Growth Projections - Jiaokong Technology anticipates a net profit increase of 86.44% for 2025 [1] - Boya Precision expects a net profit growth of 82.68%-128.36% for 2025 [1] - Huaxin Co. forecasts a net profit increase of 77.48% for 2025 [1] - Qingdao Danone anticipates a net profit growth of 77.47%-104.36% for 2025 [1] - Shenling Environment expects a net profit increase of 77.39%-112.87% for 2025 [1] Group 4: Companies with Further Profit Growth Projections - Keli Yuan anticipates a net profit increase of 72.76%-102.20% for 2025 [1] - Lante Optics expects a net profit growth of 70.04%-81.38% for 2025 [1] - Delijia forecasts a net profit increase of approximately 52.80% for 2025 [1] - Zhongke Electric anticipates a net profit growth of 50%-70% for 2025 [1] - Junsheng Electronics expects a net profit increase of 40.56%-1.35 billion for 2025 [1] Group 5: Companies with Lower Growth Expectations - Shanghai Yanpu anticipates a net profit increase of 35.44%-55% for 2025 [1] - Guotai Group expects a net profit growth of 30%-50% for 2025 [1] - Jiuan Medical anticipates a net profit increase of 21.05%-40.83% for 2025 [1] - AVIC Chengfei expects a net profit growth of 5.47%-11.67% for 2025 [1]

Core Viewpoint - YXTT (002727.SZ) forecasts a net profit attributable to shareholders of 260 million to 330 million yuan for the fiscal year 2025, representing a year-on-year growth of 127.79% to 189.12% [1] Financial Performance - The company expects a net profit after deducting non-recurring gains and losses to be between 230 million and 300 million yuan [1]

智通财经APP讯，一心堂(002727.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 2.6亿元至3.3亿元，同比增长127.79%至189.12%;扣除非经常性损益后的净利润2.3亿元至3亿元。 ...